MetaCap

Candel Therapeutics (CADL) vs REGENXBIO (RGNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Candel Therapeutics (CADL) has outperformed REGENXBIO (RGNX) over the past year, gaining 10.8% versus a loss of 39.3%. Over five years, CADL leads with a -48.5% price change compared with -76.9% for RGNX. REGENXBIO is the larger company by market cap ($473.4 million vs $395.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CADL+10.77%RGNX-39.32%
+215%+75%-65%
Nov 21, 20251 yearNov 20, 2026
CADL-53.63%RGNX-78.63%
+27%-36%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CADL versus RGNX key metrics
MetricCADLRGNX
Share price$5.04$7.16
Market cap$395.37M$473.44M
1-day change-1.75%-0.28%
YTD return-10.80%-50.28%
1-year return+10.77%-39.32%
5-year return-48.47%-76.87%
EPS (TTM)$-1.53$-3.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$170.44M
Revenue growth (YoY)—+104.54%
Net income (latest FY)$-38.18M$-193.88M
Operating margin—-94.58%
Net margin—-113.75%
52-week high$14.00$16.19
52-week low$4.35$5.46
Distance from 52-week high-64.00%-55.78%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+250.60%+198.88%
Average volume1.26M1.39M
Shares outstanding78.45M66.12M
Employees55371
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CADL has outperformed RGNX by 50.1 percentage points over the past year.

About Candel Therapeutics

CADL stock →

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees

About REGENXBIO

RGNX stock →

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees

CADL vs RGNX FAQ

Which is bigger, Candel Therapeutics or REGENXBIO?

REGENXBIO (RGNX) is larger, with a market capitalization of $473.44M compared with $395.37M for Candel Therapeutics (CADL).

Which stock has performed better over the past year, CADL or RGNX?

CADL returned +10.77% over the past 12 months, compared with -39.32% for RGNX (price return, excluding dividends). Past performance does not predict future results.

Are Candel Therapeutics and REGENXBIO in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons